{"metadata": {"organization_names": ["n.v. organon", "akzo nobel n.v.", "background technology", "the program materials"], "person_names_verified": [], "organization_names_verified": ["schering corporation", "lexicon pharmaceuticals, inc.", "merck & co.", "schering-plough.", "the joint research committee", "joint research project team", "schering-plough. schering-plough", "plough background technology", "schering-plough for development", "total manufacturing industries", "schering-plough background materials", "schering-plough corporation", "schering-plough", "schering-plough research institute", "schering-plough background technology", "lexicon background technology", "schering-plough\u2019s biotherapeutics research", "lexicon background materials"], "vars": {"Party": {"Lexicon Pharmaceuticals, Inc. (formerly known as Lexicon Genetics Incorporated)": "[[Party 1]]", "INTERVET INC.": "[[Party 2]]"}}, "entities_rejected": [], "person_names": [], "agreement_id": "dafa98a9c527caff9f8ac3a8fd6611aea2102dae2d01cee500ccbca292f9f373", "topics": [], "terms": ["**(U.S. Dollars)**", "**Additional Rights to Use of Mutant Mice**", "**Administration**", "**Annual Commercialization Reports**", "**Annual Development Reports**", "**Applicable Law**", "**Assignment and Transfer of Materials, Information and Regulatory Filings**", "**Assignment**", "**Audits**", "**Biotherapeutics Research Plans**", "**Blocked Currency**", "**By Lexicon**", "**By Schering-Plough**", "**Cardiology**", "**Change of Control of Lexicon**", "**Change of Control of Schering-Plough.**", "**Change of Control**", "**Collaboration Committees**", "**Collaboration Records**", "**Collaboration Term**", "**Collaboration and License Agreement**", "**Conduct of Collaboration**", "**Cooperation**", "**Counterparts**", "**Cumulative Annual Net Sales in the Territory of a Collaboration Product in a Contract Year**", "**Decisions**", "**Diligent Efforts**", "**Disclosure of Collaboration Results**", "**Dispute Resolution**", "**Effect of Expiration or Termination of Agreement**", "**Effect of Failure to Satisfy Diligence Obligations**", "**Effect of an Event of Default**", "**Efforts**", "**Enforcement of the Program Patent Rights**", "**Entire Agreement**", "**Events of Default**", "**Exclusivity**", "**Exhibit 1.40**", "**Exhibit 1.41**", "**Expenses**", "**Exports**", "**Force Majeure**", "**General**", "**Generation and Analysis of Mutant Mice**", "**Grants of Development and Commercialization Licenses**", "**Grants of Research Licenses for Purposes of Collaboration.**", "**Hatch-Waxman Notifications**", "**Headings**", "**Immunology**", "**Injunctive Relief**", "**Insurance**", "**Interest on Late Payments**", "**Inventorship**", "**Joint Management Committee**", "**Joint Research Committee**", "**LEXICON PHARMACEUTICALS, INC.**", "**Level 1 Phenotypic Analysis**", "**Level 2 Phenotypic Analysis**", "**Lexicon Diligence**", "**Lexicon Indemnity Obligations**", "**Limitation on Indemnity Obligations**", "**Limitations**", "**Limited Liability**", "**Manner of Payment**", "**Material Transfer**", "**Meetings of Collaboration Committees**", "**Metabolism and Endocrinology**", "**Milestone Event**", "**Milestone Payments with Respect to Collaboration Products**", "**Milestone Payments with Respect to Reverted Products**", "**Minutes**", "**N.V. ORGANON**", "**Neurology**", "**No Grant of Other Technology or Patent Rights**", "**No Partnership**", "**Non-Product-Related Infringement**", "**Nondisclosure Obligations**", "**Notices of Other Proceedings**", "**Notices of Third Party Infringement**", "**Notices**", "**Objectives**", "**Oncology**", "**Ophthalmology**", "**Other Notifications**", "**Ownership by Lexicon of the Lexicon Background Materials and Lexicon Background Technology**", "**Ownership by Schering-Plough of the Schering-Plough Background Materials and Schering-Plough Background Technology**", "**Ownership of Intellectual Property**", "**Ownership of Program Intellectual Property**", "**Ownership of Program Technology and Program Intellectual Property**", "**Patent Prosecution Costs**", "**Patent Term Extension**", "**Payment Amount**", "**Payment for Mice Requested by Schering-Plough; Funding of Biotherapeutics Research Program Costs and Target Function Discovery Program Costs**", "**Primary Prosecution Rights**", "**Procedure**", "**Product-Related Infringement**", "**Program Directors**", "**Prosecution and Maintenance of Program Patent Rights**", "**Publication**", "**Publicity**", "**Quorum; Voting**", "**Regulatory Matters**", "**Release and Reversion of Program Targets**", "**Released Targets Freedom to Operate and Research License**", "**Replacement of Collaboration Committee Representatives and Program Directors**", "**Reporting and Oversight of Target Function Discovery Program Progress**", "**Reports**", "**Representations, Warranties and Covenants of Lexicon**", "**Representations, Warranties and Covenants of Schering-Plough**", "**Requests for Mice for Released Targets**", "**Required Disclosure**", "**Resources**", "**Responsibilities of Joint Management Committee**", "**Responsibilities of Joint Research Committee**", "**Right of Review**", "**Royalties Payable with Respect to Collaboration Products.**", "**Royalties Payable with Respect to Reverted Products.**", "**Royalty Payment Terms**", "**Royalty Rate**", "**Royalty Rates**", "**Royalty Reporting and Payment**", "**Royalty Reports**", "**Royalty Term**", "**SCHERING CORPORATION,**", "**Schering-Plough Indemnity Obligations**", "**Secondary Prosecution Rights**", "**Selection of Collaboration Products for Development**", "**Severability**", "**Subcontractors**", "**Target Function Discovery Program Term**", "**Term of Agreement**", "**Term**", "**Termination and Deemed Satisfaction of Cost Sharing Arrangements under Predecessor Agreement**", "**Third Party Licenses**", "**Use of Target Function Discovery Program Data**", "**Waiver**", "**Warranty Disclaimer**", "**Withholding Taxes**", "**]   \\centered [**", "**] (but no longer than [**", "**] Program Targets as Released Targets effective as of the Effective Date. Upon the request of Schering-Plough at any time with respect to any other Program Target that has not become a Reverted Target, the Joint Management Committee will consider in good faith whether such Program Target should be designated as a Released Target, and may, by unanimous agreement of its members, designate such Program Target as a Released Target, effective as of the date of such designation. In the absence of such a designation, Schering-Plough may, at its option, designate any such Program Target as a Released Target by delivering written notice of such designation to Lexicon, and such Program Target shall become a Released Target [**", "**] after each [**", "**] after receipt of written notice of delinquency, then the applicable interest rate shall be [**", "**] after such transaction, or [**", "**] after such written notice is given to such party, the other party shall deposit such royalty payment in local currency to the credit of the party owed such payment in a recognized banking institution designated by such party, or if none is designated by such party within the [**", "**] after the date such payments are due under this Agreement at a rate equal to [**", "**] after the initial referral of such matter to the designated officers, such person(s) shall select a single inde pendent Third Party arbitrator, who shall be a professional with appropriate experience in the subject matter at issue in such disagreement. Within [**", "**] after the initial referral of such matter to the designated officers. If the parties are unable to mutually agree upon one such person, then each party shall appoint one independent Third Party professional with appropriate experience in the subject matter at issue in such disagreement prior to the expiration of such [**", "**] after written notice thereof by the non-breaching party ([**", "**] and Greater   \\centered [**", "**] before its intended submission for publication or presentation. The Reviewing Party shall have [**", "**] encoded by any such gene, and (c) any [**", "**] for each line of Mutant Mice requested by Schering-Plough in accordance with Section 4.3 to cover Lexicon\u2019s costs for the rederivation, breeding and shipment of such mice. Lexicon shall deliver to Schering-Plough an invoice for such amount upon shipment. Schering-Plough shall pay Lexicon the invoiced amount within [**", "**] from such gene [**", "**] is not practicable, if such party fails to commence and diligently pursue such remediation during such [**", "**] of the date Lexicon received such independent certified public accountant\u2019s written report so co ncluding, unless such report contains demonstrable error. The fees charged by such independent certified public accountant shall be paid by Lexicon unless such audit discloses an underpayment of more than [**", "**] of the date Schering-Plough received such independent certified public account ant\u2019s written report so concluding, unless such report contains demonstrable error. The fees charged by such independent certified public accountant shall be paid by Schering-Plough unless such audit discloses an underpayment of more than [**", "**] of the end of each [**", "**] of the occurrence of such event and make the associated milestone payment within [**", "**] or (z) [**", "**] period, the matter shall be referred to a Third Party arbitrator or arbitrators, in accordance with the following procedures, whose decision shall be [**", "**] prior to the commencement of such Contract Year. The Biotherapeutics Research Plan for the First Contract Year shall be prepared by the Joint Research Committee and approved by the Joint Management Committee within [**", "**] prior to the date of such request. Each party shall use commercially reasonable efforts to schedule all such verifications within [**", "**] representatives designated by Schering-Plough and [**", "**] shall be due and payable at the time the applicable report under Section 10.4.3.1 for such [**", "**] shall be due and payable at the time the applicable report under Section 10.6.3.1 for such [**", "**] to less than U.S. $[**", "**], (B) relating to [**", "**], or as frequently as the parties deem appropriate, on such dates and at such times as the parties shall agree, on [**", "**], then Schering-Plough would pay to Lexicon royalties of U.S. $[**", "**], to the Joint Management Committee detailing its activities under the Target Function Discovery Program. Each party shall submit reports, not less than [**", "**]. Schering-Plough shall pay Lexicon the invoiced amount within [**", "**]. The report of Lexicon\u2019s independent certified public accountant shall be made available to both parties. Subject to Schering-Plough\u2019s rights under Section 16.7, in the event Lexicon\u2019s independent certified public accountant concludes that additional amounts were owed to Lexicon for such period, the additional amounts shall be paid by Schering-Plough within [**", "**]. The report of Schering-Plough\u2019s independent certified public accountant shall be made available to both parties. Subject to Lexicon\u2019s rights under Section 16.7, in the event Schering-Plough\u2019s independent certified public accountant concludes that additional amounts were owed to Schering-Plough for such period, the additional amounts shall be paid by Lexicon within [**", "\u201c**Acquisition Effective Date**\u201d", "\u201c**Affiliate**\u201d", "\u201c**Agreement**\u201d", "\u201c**Antibody**\u201d", "\u201c**Antisense Compound**\u201d", "\u201c**BLA**\u201d", "\u201c**Background Materials**\u201d", "\u201c**Background Technology**\u201d", "\u201c**Biotherapeutics Research Plan**\u201d", "\u201c**Biotherapeutics Research Program Costs**\u201d", "\u201c**Biotherapeutics Research**\u201d", "\u201c**Collabo ration Term**\u201d", "\u201c**Collaboration Committee**\u201d", "\u201c**Collaboration Product**\u201d", "\u201c**Collaboration Term**\u201d", "\u201c**Collaboration**\u201d", "\u201c**Combination Product**\u201d", "\u201c**Commercialization**\u201d", "\u201c**Commercialize**\u201d", "\u201c**Confidential Information**\u201d", "\u201c**Contract Quarters**\u201d", "\u201c**Contract Year**\u201d", "\u201c**Control**\u201d", "\u201c**Controlled**\u201d", "\u201c**Cover**", "\u201c**Covered**\u201d", "\u201c**Covering**\u201d", "\u201c**Develop**\u201d", "\u201c**Development**\u201d", "\u201c**Diligent Efforts**\u201d", "\u201c**Disclosing Party**\u201d", "\u201c**EMEA**\u201d", "\u201c**Effective Date**\u201d", "\u201c**Event of Default**\u201d", "\u201c**FDA**\u201d", "\u201c**FDC Act**\u201d", "\u201c**FTE Costs**\u201d", "\u201c**FTE Rate**\u201d", "\u201c**FTE**\u201d", "\u201c**Field**\u201d", "\u201c**First Commercial Sale**\u201d", "\u201c**First Contract Year**\u201d", "\u201c**GAAP**\u201d", "\u201c**IND**\u201d", "\u201c**Indemnitee**\u201d", "\u201c**Indemnitor**\u201d", "\u201c**Joint Management Committee**\u201d", "\u201c**Joint Research Committee**\u201d", "\u201c**Joint Research Project Team**\u201d", "\u201c**Laws**\u201d", "\u201c**Level 1 Phenotypic Analysis**\u201d", "\u201c**Level 2 Phenotypic Analysis**\u201d", "\u201c**Lexicon Background Materials**\u201d", "\u201c**Lexicon Background Technology**\u201d", "\u201c**Lexicon**\u201d", "\u201c**Major Market**\u201d", "\u201c**Mutant Mouse**\u201d", "\u201c**Net Sales**\u201d", "\u201c**Patent Prosecution**\u201d", "\u201c**Patent Rights**\u201d", "\u201c**Phase 1 Clinical Trial**\u201d", "\u201c**Phase 2 Clinical Trial**\u201d", "\u201c**Phase 3 Clinical Trial**\u201d", "\u201c**Post-Approval Study**\u201d", "\u201c**Predecessor Agreement Effective Date**\u201d", "\u201c**Predecessor Agreement**\u201d", "\u201c**Program Antibody**\u201d", "\u201c**Program Antisense Compound**\u201d", "\u201c**Program Director**\u201d", "\u201c**Program Intellectual Property**\u201d", "\u201c**Program Materials**\u201d", "\u201c**Program Patent Rights**\u201d", "\u201c**Program Protein**\u201d", "\u201c**Program Target**\u201d", "\u201c**Program Technology**\u201d", "\u201c**Protein**\u201d", "\u201c**Receiving Party**\u201d", "\u201c**Regulatory Approval**\u201d", "\u201c**Regulatory Authority**\u201d", "\u201c**Released Product**\u201d", "\u201c**Released Target**\u201d", "\u201c**Representatives**\u201d", "\u201c**Reverted Product**\u201d", "\u201c**Reverted Target**\u201d", "\u201c**Reviewing Party**\u201d", "\u201c**Schering-Plough Background Materials**\u201d", "\u201c**Schering-Plough Background Technology**\u201d", "\u201c**Schering-Plough**\u201d", "\u201c**Small Molecule Compound**\u201d", "\u201c**Submitting Party**\u201d", "\u201c**Target Function Discovery Program Costs**\u201d", "\u201c**Target Function Discovery Program Term**\u201d", "\u201c**Target Function Discovery Program**\u201d", "\u201c**Territory**\u201d", "\u201c**Therapeutic Area**\u201d", "\u201c**Third Party**\u201d", "\u201c**Valid Claim**\u201d", "\u201cIntervet\u201d", "\u201cOrganon\u201d", "\u201cSPRI\u201d"]}}